MOBILE, Ala. — A special story about a three-year-old boy who needs the public’s help. Alijah Cunningham was born with a rare disease that caused him to lose all of his fingers and toes. Now, his parents are on a journey to gift him with what he lost. But you...
Latest News
SAN FRANCISCO, Calif. – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced key development milestones for its THRV-1268 clinical program: patient dosing has commenced in the Phase 2/3 Wave II clinical study evaluating THRV-1268...
MONTREAL, Canada – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the initiation of the Wave II clinical study, a pivotal Phase 2/3 clinical research study in adults diagnosed with Long QT Syndrome Type 2...
By Raffaele Pereno STOCKHOLM, Sweden – Reporting at BioEurope 2024, CheckOrphan had the opportunity to meet a promising biotech company, whose lead product seeks to stop the progression of amyotrophic lateral sclerosis (ALS) in its tracks. Tikomed AB is a privately owned pharmaceutical company based in Viken, Sweden. Adam Bruce,...
HELSINKI, Finland — TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has been selected by the U.S. Department of Defense (DOD), America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset. The...
Madrid, Spain – Restricting the eating window to 8 hours a day significantly improves blood glucose control in adults at risk of type 2 diabetes irrespective of whether it is earlier or later in the day, according to a randomised crossover trial to be presented at this year’s Annual Meeting...
New York, NY—August 20, 2024—Cardiovascular disease is the leading cause of death in patients suffering from lupus, an autoimmune disease in which our immune system attacks our own tissues and organs, the heart, blood, lung, joints, brain, and skin. Lupus myocarditis–inflammation of the heart muscle– can be very serious because...
Johns Hopkins brain scientists have figured out why a faulty protein accumulates in cells everywhere in the bodies of people with Huntington’s disease (HD), but only kills cells in the part of the brain that controls movement, causing negligible damage to tissues elsewhere. The answer, reported this week in Science,...
Gothenburg, Sweden – Proteins that form clumps occur in many difficult-to-treat diseases, such as ALS, Alzheimer’s, and Parkinson’s. The mechanisms behind how the proteins interact with each other are difficult to study, but now researchers at Chalmers University of Technology, Sweden, have discovered a new method for capturing many proteins...
CAMBRIDGE, Mass. — Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare mitochondrial disease MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The study enrolled 43 participants, and...